{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:45:14Z","timestamp":1792100714811,"version":"4.4.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2025-I2M-KJ-012"],"award-info":[{"award-number":["2025-I2M-KJ-012"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32270915"],"award-info":[{"award-number":["32270915"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.critrevonc.2026.105636","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:42:31Z","timestamp":1791319351000},"page":"105636","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["\u03b3\u03b4 T cells in cancer immunotherapy, 2000\u20132025: A bibliometric analysis and clinical-trial evidence map"],"prefix":"10.1016","volume":"228","author":[{"given":"Yuheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8424-2654","authenticated-orcid":false,"given":"Yuanzhi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengjie","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiadi","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2410-5408","authenticated-orcid":false,"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105636_bib1","unstructured":"Adicet Bio, Inc., 2024. Quarterly Report on Form 10-Q for the quarter ended September 30, 2024. U.S. Securities and Exchange Commission. Available from: https:\/\/www.sec.gov\/Archives\/edgar\/data\/1720580\/000095017024122253\/acet-20240930.htm."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105636_bib2","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jcyt.2024.04.072","article-title":"Glycolysis inhibition affects proliferation and cytotoxicity of V\u03b39V\u03b42 T cells expanded for adoptive cell therapy","volume":"26","author":"Aehnlich","year":"2024","journal-title":"Cytotherapy"},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105636_bib3","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1158\/1078-0432.CCR-16-0597","article-title":"Delta One T cells for immunotherapy of chronic lymphocytic leukemia: clinical-grade expansion\/differentiation and preclinical proof of concept","volume":"22","author":"Almeida","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105636_bib4","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3390\/cells14161242","article-title":"Chimeric antigen receptor T cell immunotherapy for autoimmune rheumatic disorders: where are we now?","volume":"14","author":"Anyfanti","year":"2025","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105636_bib5","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.joi.2017.08.007","article-title":"bibliometrix: an R-tool for comprehensive science mapping analysis","volume":"11","author":"Aria","year":"2017","journal-title":"J. Informetr."},{"issue":"5428","key":"10.1016\/j.critrevonc.2026.105636_bib6","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1126\/science.285.5428.727","article-title":"Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA","volume":"285","author":"Bauer","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105636_bib7","unstructured":"Adicet Bio, 2021. A Phase 1 Study of ADI-001 in B Cell Malignancies [clinical trial registration]. ClinicalTrials.gov Identifier: NCT04735471. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04735471. Registry record."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105636_bib8","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202000680","article-title":"Single-cell RNA sequencing of human breast tumour-infiltrating immune cells reveals a \u03b3\u03b4 T-cell subtype associated with good clinical outcome","volume":"4","author":"Boufea","year":"2020","journal-title":"Life Sci. Alliance"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105636_bib9","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1073\/pnas.0810059106","article-title":"Cross-presenting human \u03b3\u03b4 T cells induce robust CD8+ \u03b1\u03b2 T cell responses","volume":"106","author":"Brandes","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105636_bib10","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ymthe.2017.12.001","article-title":"Chimeric antigen receptor-engineered human gamma delta T cells: enhanced cytotoxicity with retention of cross presentation","volume":"26","author":"Capsomidis","year":"2018","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105636_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109871","article-title":"NKG2A expression identifies a subset of human V\u03b42 T cells exerting the highest antitumor effector functions","volume":"37","author":"Cazzetta","year":"2021","journal-title":"Cell. Rep."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105636_bib12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/asi.20317","article-title":"CiteSpace II: Detecting and visualizing emerging trends and transient patterns in scientific literature","volume":"57","author":"Chen","year":"2006","journal-title":"J. Am. Soc. Inf. Sci. Technol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105636_bib13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2014.03.007","article-title":"Gammadelta (\u03b3\u03b4) T lymphocytes do not impact the development of early atherosclerosis","volume":"234","author":"Cheng","year":"2014","journal-title":"Atherosclerosis"},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105636_bib14","doi-asserted-by":"crossref","first-page":"8903","DOI":"10.3390\/ijms21238903","article-title":"A cell for the ages: human \u03b3\u03b4 T cells across the lifespan","volume":"21","author":"Clark","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105636_bib15","unstructured":"ClinicalTrials.gov, 2025. A study of LAVA-051 in patients with relapsed or refractory chronic lymphocytic leukemia, multiple myeloma, or acute myeloid leukemia. Identifier NCT04887259; study history. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04887259?a=13&tab=history."},{"issue":"7556","key":"10.1016\/j.critrevonc.2026.105636_bib16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature14282","article-title":"IL-17-producing \u03b3\u03b4 T cells and neutrophils conspire to promote breast cancer metastasis","volume":"522","author":"Coffelt","year":"2015","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105636_bib17","doi-asserted-by":"crossref","first-page":"16812","DOI":"10.1074\/jbc.M111.327650","article-title":"Ectopically expressed human tumor biomarker MutS homologue 2 is a novel endogenous ligand that is recognized by human \u03b3\u03b4 T cells to induce innate anti-tumor\/virus immunity","volume":"287","author":"Dai","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105636_bib18","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.cell.2016.07.046","article-title":"\u03b3\u03b4 T cells support pancreatic oncogenesis by restraining \u03b1\u03b2 T cell activation","volume":"166","author":"Daley","year":"2016","journal-title":"Cell"},{"issue":"616","key":"10.1016\/j.critrevonc.2026.105636_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj0835","article-title":"Development of ICT01, a first-in-class, anti-BTN3A antibody for activating V\u03b39V\u03b42 T cell-mediated antitumor immune response","volume":"13","author":"De Gassart","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105636_bib20","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3389\/fimmu.2014.00636","article-title":"Clinical applications of gamma delta T cells with multivalent immunity","volume":"5","author":"Deniger","year":"2014","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105636_bib21","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105636_bib22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cell.2016.08.030","article-title":"Epithelia use butyrophilin-like molecules to shape organ-specific \u03b3\u03b4 T cell compartments","volume":"167","author":"Di Marco Barros","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105636_bib23","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jbusres.2021.04.070","article-title":"How to conduct a bibliometric analysis: an overview and guidelines","volume":"133","author":"Donthu","year":"2021","journal-title":"J. Bus. Res."},{"key":"10.1016\/j.critrevonc.2026.105636_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.863155","article-title":"A simple and robust single-step method for CAR-V\u03b41 \u03b3\u03b4T cell expansion and transduction for cancer immunotherapy","volume":"13","author":"Ferry","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105636_bib25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1084\/jem.20021500","article-title":"Human T cell receptor \u03b3\u03b4 cells recognize endogenous mevalonate metabolites in tumor cells","volume":"197","author":"Gober","year":"2003","journal-title":"J. Exp. Med."},{"issue":"5357","key":"10.1016\/j.critrevonc.2026.105636_bib26","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1126\/science.279.5357.1737","article-title":"Recognition of stress-induced MHC molecules by intestinal epithelial \u03b3\u03b4 T cells","volume":"279","author":"Groh","year":"1998","journal-title":"Science"},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105636_bib27","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1182\/blood-2012-05-432427","article-title":"\u03b39 and \u03b42CDR3 domains regulate functional avidity of T cells harboring \u03b39\u03b42TCRs","volume":"120","author":"Grunder","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105636_bib28","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1097\/JS9.0000000000003668","article-title":"Current concerns and future directions of large language model ChatGPT in medicine: a machine-learning-driven global-scale bibliometric analysis","volume":"112","author":"Guo","year":"2026","journal-title":"Int. J. Surg."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105636_bib29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12943-024-02140-6","article-title":"Artificial intelligence AlphaFold model for molecular biology and drug discovery: a machine-learning-driven informatics investigation","volume":"23","author":"Guo","year":"2024","journal-title":"Mol. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105636_bib30","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2012-05-430470","article-title":"Key implication of CD277\/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human \u03b3\u03b4 T-cell subset","volume":"120","author":"Harly","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105636_bib31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.4049\/jimmunol.1800934","article-title":"\u03b3\u03b4 T cell update: adaptive orchestrators of immune surveillance","volume":"203","author":"Hayday","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105636_bib32","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2119\/molmed.2016.00023","article-title":"TCR\u03b34\u03b41-engineered \u03b1\u03b2T cells exhibit effective antitumor activity","volume":"22","author":"He","year":"2016","journal-title":"Mol. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105636_bib33","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105636_bib34","unstructured":"IN8bio, 2019. A study of INB-200 (autologous gamma-delta T cells) in subjects with newly diagnosed glioblastoma [clinical trial registration]. ClinicalTrials.gov Identifier: NCT04165941. First posted 2019. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04165941. Registry record."},{"issue":"29","key":"10.1016\/j.critrevonc.2026.105636_bib35","doi-asserted-by":"crossref","first-page":"25611","DOI":"10.1074\/jbc.M111.239624","article-title":"Flanking V and J sequences of complementary determining region 3 of T-cell receptor (TCR) \u03b41 (CDR3\u03b41) determine the structure and function of TCR\u03b34\u03b41","volume":"286","author":"Jiang","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105636_bib36","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s42255-025-01276-z","article-title":"Metabolic reprogramming of interleukin-17-producing \u03b3\u03b4 T cells promotes ACC1-mediated de novo lipogenesis under psoriatic conditions","volume":"7","author":"Kao","year":"2025","journal-title":"Nat. Metab."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105636_bib37","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00262-006-0199-6","article-title":"Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma","volume":"56","author":"Kobayashi","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105636_bib38","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood-2008-12-196287","article-title":"The NKG2D ligand ULBP4 binds to TCR\u03b39\/\u03b42 and induces cytotoxicity to tumor cells through both TCR\u03b3\u03b4 and NKG2D","volume":"114","author":"Kong","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105636_bib39","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood.V96.2.384.013k07_384_392","article-title":"Stimulation of \u03b3\u03b4 T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma","volume":"96","author":"Kunzmann","year":"2000","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105636_bib40","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.4049\/jimmunol.2200185","article-title":"Cutting edge: bispecific \u03b3\u03b4 T cell engager containing heterodimeric BTN2A1 and BTN3A1 promotes targeted activation of V\u03b39V\u03b42+ T cells in the presence of costimulation by CD28 or NKG2D","volume":"209","author":"Lai","year":"2022","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105636_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051805","article-title":"Engineered drug resistant \u03b3\u03b4 T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy","volume":"8","author":"Lamb","year":"2013","journal-title":"PLoS. One"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105636_bib42","article-title":"A bispecific T cell engager recruits both type 1 NKT and V\u03b39V\u03b42 T cells for the treatment of CD1d-expressing hematological malignancies","volume":"4","author":"Lameris","year":"2023","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.critrevonc.2026.105636_bib43","unstructured":"LAVA Therapeutics, 2024. LAVA Therapeutics announces discontinuation of LAVA-1207 program and strategic portfolio prioritization. December 2024. Available from: https:\/\/ir.lavatherapeutics.com\/node\/8156\/pdf."},{"key":"10.1016\/j.critrevonc.2026.105636_bib44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1748-5908-5-69","article-title":"Scoping studies: advancing the methodology","volume":"5","author":"Levac","year":"2010","journal-title":"Implement. Sci."},{"key":"10.1016\/j.critrevonc.2026.105636_bib45","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41467-024-45449-y","article-title":"Tumor reactive \u03b3\u03b4 T cells contribute to a complete response to PD-1 blockade in a Merkel cell carcinoma patient","volume":"15","author":"Lien","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105636_bib46","article-title":"Bibliometric analysis of \u03b3\u03b4 T cells as immune regulators in cancer prognosis","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105636_bib47","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41590-020-00848-3","article-title":"Distinct metabolic programs established in the thymus control effector functions of \u03b3\u03b4 T cell subsets in tumor microenvironments","volume":"22","author":"Lopes","year":"2021","journal-title":"Nat. Immunol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105636_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003441","article-title":"Off-the-shelf V\u03b41 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma","volume":"9","author":"Makkouk","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105636_bib49","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105636_bib50","doi-asserted-by":"crossref","first-page":"TPS2672","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2672","article-title":"Phase I\/II trial of LAVA-1207, a novel bispecific gamma-delta T-cell engager alone, or with low dose IL-2 or pembrolizumab, in metastatic castration resistant prostate cancer (mCRPC)","volume":"42","author":"Mehra","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105636_bib51","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/s41590-018-0253-5","article-title":"The \u03b3\u03b4TCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness","volume":"19","author":"Melandri","year":"2018","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105636_bib52","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/s41423-022-00894-x","article-title":"Glucose metabolism controls human \u03b3\u03b4 T-cell-mediated tumor immunosurveillance in diabetes","volume":"19","author":"Mu","year":"2022","journal-title":"Cell. Mol. Immunol."},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105636_bib53","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105636_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1373","article-title":"Allogeneic CD20-targeted \u03b3\u03b4 T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models","volume":"11","author":"Nishimoto","year":"2022","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105636_bib55","article-title":"Tumor-restricted activation of V\u03b39V\u03b42 T cells via bispecific Evobodies: a novel strategy for safe and potent immunotherapy in ovarian cancer","volume":"16","author":"Oberg","year":"2025","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105636_bib56","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s12276-021-00576-0","article-title":"Function of \u03b3\u03b4 T cells in tumor immunology and their application to cancer therapy","volume":"53","author":"Park","year":"2021","journal-title":"Exp. Mol. Med."},{"issue":"44","key":"10.1016\/j.critrevonc.2026.105636_bib57","doi-asserted-by":"crossref","first-page":"12520","DOI":"10.1073\/pnas.1607136113","article-title":"Human V\u03b42 T cells are a major source of interleukin-9","volume":"113","author":"Peters","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105636_bib58","doi-asserted-by":"crossref","first-page":"11906","DOI":"10.1073\/pnas.1818488116","article-title":"Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRV\u03b41 and TCRV\u03b42 \u03b3\u03b4 T lymphocytes","volume":"116","author":"Pizzolato","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2026.105636_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2024.101072","article-title":"Systematic analysis of human colorectal cancer scRNA-seq revealed limited pro-tumoral IL-17 production potential in gamma delta T cells","volume":"58","author":"Ran","year":"2024","journal-title":"Neoplasia"},{"issue":"6478","key":"10.1016\/j.critrevonc.2026.105636_bib60","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay5516","article-title":"Butyrophilin 2A1 is essential for phosphoantigen reactivity by \u03b3\u03b4 T cells","volume":"367","author":"Rigau","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105636_bib61","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3389\/fimmu.2020.01347","article-title":"Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia","volume":"11","author":"Rozenbaum","year":"2020","journal-title":"Front. Immunol."},{"issue":"35","key":"10.1016\/j.critrevonc.2026.105636_bib62","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105636_bib63","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41573-019-0038-z","article-title":"Translating gammadelta (\u03b3\u03b4) T cells and their receptors into cancer cell therapies","volume":"19","author":"Sebestyen","year":"2020","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105636_bib64","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105636_bib65","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nri3904","article-title":"\u03b3\u03b4 T cells in cancer","volume":"15","author":"Silva-Santos","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105636_bib66","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.1038\/s41467-024-51025-1","article-title":"Dysfunctional tumor-infiltrating V\u03b41+ T lymphocytes in microsatellite-stable colorectal cancer","volume":"15","author":"Stary","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105636_bib67","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3389\/fimmu.2018.01062","article-title":"GMP-grade manufacturing of T cells engineered to express a defined \u03b3\u03b4TCR","volume":"9","author":"Straetemans","year":"2018","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105636_bib68","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2326-6066.CIR-22-0644","article-title":"\u03b2-Catenin drives butyrophilin-like molecule loss and \u03b3\u03b4 T-cell exclusion in colon cancer","volume":"11","author":"Suzuki","year":"2023","journal-title":"Cancer Immunol. Res."},{"issue":"6527","key":"10.1016\/j.critrevonc.2026.105636_bib69","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/375155a0","article-title":"Natural and synthetic non-peptide antigens recognized by human \u03b3\u03b4 T cells","volume":"375","author":"Tanaka","year":"1995","journal-title":"Nature"},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105636_bib70","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105636_bib71","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105636_bib72","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cellimm.2015.01.008","article-title":"Human V\u03b39\/V\u03b42 T cells: innate adaptors of the immune system","volume":"296","author":"Tyler","year":"2015","journal-title":"Cell. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105636_bib73","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105636_bib74","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nri3384","article-title":"Six-of-the-best: unique contributions of \u03b3\u03b4 T cells to immunology","volume":"13","author":"Vantourout","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105636_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109416","article-title":"\u03b3\u03b4T cells are prevalent in the proximal aorta and drive nascent atherosclerotic lesion progression and neutrophilia in hypercholesterolemic mice","volume":"9","author":"Vu","year":"2014","journal-title":"PLoS. One"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105636_bib76","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1016\/j.clml.2023.02.003","article-title":"A Phase I Trial of Allogeneic \u03b3\u03b4 T Lymphocytes From Haploidentical Donors in Patients With Refractory or Relapsed Acute Myeloid Leukemia","volume":"23","author":"Vydra","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2026.105636_bib77","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41392-023-01646-7","article-title":"Anti-PD-1 antibody armored \u03b3\u03b4 T cells enhance anti-tumor efficacy in ovarian cancer","volume":"8","author":"Wang","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105636_bib78","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/blood-2002-12-3665","article-title":"\u03b3\u03b4 T cells for immune therapy of patients with lymphoid malignancies","volume":"102","author":"Wilhelm","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105636_bib79","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.immuni.2019.09.006","article-title":"Butyrophilin-like 3 directly binds a human V\u03b34+ T cell receptor using a modality distinct from clonally-restricted antigen","volume":"51","author":"Willcox","year":"2019","journal-title":"Immunity"},{"issue":"2\u20133","key":"10.1016\/j.critrevonc.2026.105636_bib80","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-3083.2007.01963.x","article-title":"Lysis of a broad range of epithelial tumour cells by human \u03b3\u03b4 T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition","volume":"66","author":"Wrobel","year":"2007","journal-title":"Scand. J. Immunol."},{"issue":"513","key":"10.1016\/j.critrevonc.2026.105636_bib81","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax9364","article-title":"An innate-like V\u03b41+ \u03b3\u03b4 T cell compartment in the human breast is associated with remission in triple-negative breast cancer","volume":"11","author":"Wu","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105636_bib82","article-title":"The role of \u03b3\u03b4 T lymphocytes in atherosclerosis","volume":"15","author":"Xu","year":"2024","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105636_bib83","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41423-025-01258-x","article-title":"\u03b3\u03b4 T-cell autoresponses to ectopic membrane proteins: a new type of pattern recognition","volume":"22","author":"You","year":"2025","journal-title":"Cell. Mol. Immunol."},{"issue":"7980","key":"10.1016\/j.critrevonc.2026.105636_bib84","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41586-023-06525-3","article-title":"Phosphoantigens glue butyrophilin 3A1 and 2A1 to activate V\u03b39V\u03b42 T cells","volume":"621","author":"Yuan","year":"2023","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105636_bib85","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/cmi.2011.28","article-title":"CDR3\u03b4-grafted \u03b39\u03b42T cells mediate effective antitumor reactivity","volume":"9","author":"Zhao","year":"2012","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105636_bib86","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/CM9.0000000000002781","article-title":"\u03b3\u03b4 T cells: Major advances in basic and clinical research in tumor immunotherapy","volume":"137","author":"Zhao","year":"2024","journal-title":"Chin. Med. J."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105636_bib87","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/1094428114562629","article-title":"Bibliometric methods in management and organization","volume":"18","author":"Zupic","year":"2015","journal-title":"Organ. Res. Methods"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:08:19Z","timestamp":1792098499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826005238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":87,"alternative-id":["S1040842826005238"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105636","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u03b3\u03b4 T cells in cancer immunotherapy, 2000\u20132025: A bibliometric analysis and clinical-trial evidence map","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105636","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105636"}}